Curt Malloy, Sr Vice President, Strategic Operations at HDT Bio, shared a post on LinkedIn:
“It was both a pleasure and an honor to moderate a panel on Public-Private Partnerships at the 2025 Binaytara Foundation’s Symposium on Global Oncology.
Our discussion focused on the feasibility and potential global impact of a therapeutic breast cancer vaccine – a technology that could transform care by preventing metastasis following treatment with Herceptin in high-income countries, and that could serve as a low-cost, accessible alternative in low- and middle-income countries.
The conversation underscored the importance of collaboration across sectors, including academic, industry, and non-profit entities, to accelerate innovation and ensure that life-saving therapies reach patients everywhere … not just those individuals in the wealthiest countries.
My sincere thanks to my fellow panelists Cathyryne Manner, Peter Berglund and Adedamola Dada for their expertise, insight, and shared commitment to advancing equity in cancer care, and to the Binaytara Foundation and Jerry Radich for creating such a thoughtful forum for global oncology leaders to exchange ideas and spark collaboration.”
More posts featuring Curt Malloy on OncoDaily.